Total Payments
$99,955
2024 Payments
$1,200
Companies
10
Transactions
86
Medicare Patients
473
Medicare Billing
$87,141
Payment Breakdown by Category
Consulting$71,125 (71.2%)
Other$19,320 (19.3%)
Travel$7,648 (7.7%)
Food & Beverage$1,842 (1.8%)
Education$19.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $71,125 | 20 | 71.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,320 | 3 | 9.3% |
| Travel and Lodging | $7,648 | 29 | 7.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,800 | 2 | 6.8% |
| Honoraria | $3,200 | 2 | 3.2% |
| Food and Beverage | $1,842 | 29 | 1.8% |
| Education | $19.81 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46,470 | 19 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $27,734 | 25 | $0 (2019) |
| Eisai Inc. | $5,990 | 14 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,390 | 14 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $4,453 | 3 | $0 (2023) |
| Exelixis Inc. | $4,269 | 7 | $0 (2018) |
| Daiichi Sankyo Inc. | $2,398 | 1 | $0 (2021) |
| ARRAY BIOPHARMA INC | $2,000 | 1 | $0 (2020) |
| Coherus Biosciences Inc. | $1,200 | 1 | $0 (2024) |
| Celgene Corporation | $50.88 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,200 | 1 | Coherus Biosciences Inc. ($1,200) |
| 2023 | $4,472 | 4 | AstraZeneca Pharmaceuticals LP ($4,453) |
| 2021 | $7,398 | 2 | Merck Sharp & Dohme Corporation ($5,000) |
| 2020 | $2,051 | 2 | ARRAY BIOPHARMA INC ($2,000) |
| 2019 | $9,427 | 7 | Novartis Pharmaceuticals Corporation ($4,802) |
| 2018 | $39,537 | 50 | Merck Sharp & Dohme Corporation ($12,951) |
| 2017 | $35,870 | 20 | Merck Sharp & Dohme Corporation ($23,875) |
All Payment Transactions
86 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/02/2024 | Coherus Biosciences Inc. | — | Honoraria | Cash or cash equivalent | $1,200.00 | General |
| 12/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 08/01/2023 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 07/11/2023 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: Oncology | ||||||
| 06/29/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 11/06/2020 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2020 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | Cash or cash equivalent | $50.88 | General |
| Category: Oncology | ||||||
| 04/04/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $4,375.00 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: ONCOLOGY | ||||||
| 01/14/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| 01/14/2019 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug) | Travel and Lodging | In-kind items and services | $1,133.00 | General |
| Category: ONCOLOGY | ||||||
| 01/14/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $118.36 | General |
| 01/14/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 01/14/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $16.00 | General |
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $4,740.00 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $442.10 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $209.05 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $206.40 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $52.32 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $49.98 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $49.98 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $48.03 | General |
| Category: Oncology | ||||||
| 12/14/2018 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $45.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 112 | 233 | $51,667 | $22,469 |
| 2022 | 3 | 115 | 253 | $63,867 | $25,687 |
| 2021 | 2 | 111 | 222 | $50,262 | $21,190 |
| 2020 | 4 | 135 | 222 | $55,566 | $17,796 |
Total Patients
473
Total Services
930
Medicare Billing
$87,141
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 65 | 165 | $40,260 | $17,786 | 44.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 51 | $9,282 | $3,808 | 41.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 17 | $2,125 | $876.01 | 41.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 70 | 184 | $44,896 | $19,613 | 43.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 34 | 58 | $10,556 | $4,385 | 41.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $8,415 | $1,689 | 20.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 72 | 159 | $38,796 | $16,979 | 43.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 39 | 63 | $11,466 | $4,210 | 36.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 58 | 118 | $29,063 | $9,960 | 34.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 49 | 74 | $13,468 | $4,541 | 33.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $10,725 | $2,359 | 22.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 13 | 15 | $2,310 | $934.59 | 40.5% |
About Dr. Aram Hezel, MD
Dr. Aram Hezel, MD is a Hematology & Oncology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1144202607.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aram Hezel, MD has received a total of $99,955 in payments from pharmaceutical and medical device companies, with $1,200 received in 2024. These payments were reported across 86 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($71,125).
As a Medicare-enrolled provider, Hezel has provided services to 473 Medicare beneficiaries, totaling 930 services with total Medicare billing of $87,141. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Rochester, NY
- Active Since 11/18/2005
- Last Updated 07/06/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1144202607
Products in Payments
- KEYTRUDA (Biological) $34,520
- AFINITOR (Drug) $17,439
- Lenvima (Drug) $5,990
- Nexavar (Drug) $5,390
- Cabometyx (Drug) $4,269
- SANDOSTATIN LAR (Drug) $4,126
- Enhertu (Drug) $2,398
- IMJUDO (Biological) $2,398
- IMFINZI (Biological) $2,055
- BRAFTOVI (Drug) $2,000
- Abraxane (Drug) $50.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rochester
Dr. Alex Spyropoulos, Md, MD
Hematology & Oncology — Payments: $750,882
Hematology & Oncology $750,882
Shaji Kumar, M.d, M.D
Hematology & Oncology — Payments: $722,278
Hematology & Oncology $722,278
David Dingli, M.d, M.D
Hematology & Oncology — Payments: $505,158
Hematology & Oncology $505,158
Amit Mahipal
Hematology & Oncology — Payments: $474,204
Hematology & Oncology $474,204
Yi Lin, M.d, M.D
Hematology & Oncology — Payments: $333,310
Hematology & Oncology $333,310
Grzegorz Nowakowski, M.d, M.D
Hematology & Oncology — Payments: $254,028
Hematology & Oncology $254,028